{
  "docId": "019de072-afcf-751b-be79-65bbe03fb0c7",
  "docSlug": "a4681640730b4446aa1f6ee077b8a572",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 23 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 23,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes a molecular visualization of the antibody-receptor interaction.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-afcf-751b-be79-65bbe03fb0c7/17",
  "deckHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7",
  "deckJsonHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7.json",
  "deckAnchorHref": "/decks/019de072-afcf-751b-be79-65bbe03fb0c7#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "image",
      "text": "Molecular structure diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fa05d89-fe3b-43a0-b5cb-b5b3c47860fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.6,
        "x": 0.03,
        "y": 0.42
      },
      "kind": "list",
      "text": "Phase 1 Study Update\nMonotherapy in the post checkpoint inhibitor patients\nMonotherapy Phase 1a multiple ascending dose study completed\nNear PR in a patient with mucosal melanoma\nProlonged stable disease in two patients with NSCLC\nMTD defined by immune thrombocytopenia\nMonotherapy Phase 1b dose expansion study nearing completion\n3 PRs observed so far: small cell lung cancer, mucosal melanoma and metastatic melanoma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37e14676-8a8b-4189-b838-2577afd5d716",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.03,
        "y": 0.24
      },
      "kind": "list",
      "text": "CTX-471: next generation CD137 agonist\nFully human, IgG4, optimized affinity for agonistic antibody\nUnique epitope: non-ligand blocking",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed0ec5c6-7130-47d2-b61c-9a8c73628ea9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "NOVEL EPITOPE WITH DIFFERENTIATED ACTIVITY OBSERVED IN EXTENSIVE PRECLINICAL DATA*",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2aa262c9-88b8-4b0b-84a7-62d5d8c3c4b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.64,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "*Eskiocak, et al. JCI Insight. 2020;5(5):e133647",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2453d462-aa3f-4afb-95f4-a7ae0c99823c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.7,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "CTX-471: Potential Best-in-Class CD137 Agonist",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc1e8d73-49c4-4463-9196-2434a6fb0e85",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "daeddc9d-50de-42be-ae24-a25cfb82c367",
      "evidence": "list/bullet: Phase 1 Study Update",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 23,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "623768d0-5f70-4f8f-9e81-1e86d7a34667",
      "evidence": "The deck presents a sense of urgency and potential benefits of investing in the company",
      "position": 0,
      "objective": "Highlight the potential consequences of not investing in Compass Therapeutics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}